Advertisement

Advertisement

AMRN Stock Latest News

Amarin Streamlines Board, Updates Director Equity Compensation Plan

Company AnnouncementsAmarin Streamlines Board, Updates Director Equity Compensation Plan

Amarin highlights new recommendation for treatment of CV risk

PremiumThe Fly

Amarin highlights new recommendation for treatment of CV risk

29d ago

Amarin to present data in patients at extreme cardiovascular risk

PremiumThe Fly

Amarin to present data in patients at extreme cardiovascular risk

1M ago

Amarin’s European Outlook Hinges on Recordati’s VAZKEPA Execution, Raising Commercial and IP Risk

PremiumCompany Announcements

Amarin’s European Outlook Hinges on Recordati’s VAZKEPA Execution, Raising Commercial and IP Risk

1M ago

Amarin Earnings Call: Cost Cuts, Cash, and Crosswinds

PremiumCompany Announcements

Amarin Earnings Call: Cost Cuts, Cash, and Crosswinds

1M ago

Amarin highlights recent data published on REDUCE-IT study

PremiumThe FlyAmarin highlights recent data published on REDUCE-IT study

1M ago

Amarin reports Q4 non-GAAP EPS 1c vs. (2c) last year

The Fly

Amarin reports Q4 non-GAAP EPS 1c vs. (2c) last year

2M ago

Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities

The Fly

Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities

2M ago

Amarin issues call to action for American Heart Month

PremiumThe Fly

Amarin issues call to action for American Heart Month

2M ago

AMRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-Earnings

AMRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?

2M ago

Amarin comments on recent innovations for patients with elevated triglycerides

PremiumThe Fly

Amarin comments on recent innovations for patients with elevated triglycerides

3M ago

Amarin expects Q4 net revenue $48M-$43M

PremiumThe Fly

Amarin expects Q4 net revenue $48M-$43M

3M ago

Amarin believes it’s in ‘best position’ to capitalize on opportunities in FY26

PremiumThe FlyAmarin believes it’s in ‘best position’ to capitalize on opportunities in FY26

3M ago

Amarin announces new post hoc analysis of aspirin use in REDUCE-IT

The Fly

Amarin announces new post hoc analysis of aspirin use in REDUCE-IT

5M ago

Amarin Corporation’s Financial Health at Risk Amid Global Trade Uncertainties

Company Announcements

Amarin Corporation’s Financial Health at Risk Amid Global Trade Uncertainties

6M ago

Amarin Corporation Reports Q3 2025 Financial Results

PremiumCompany Announcements

Amarin Corporation Reports Q3 2025 Financial Results

6M ago

Amarin Corporation’s Earnings Call Highlights Growth and Challenges

PremiumCompany Announcements

Amarin Corporation’s Earnings Call Highlights Growth and Challenges

6M ago

Amarin reports Q3 EPS (2c) vs (6c) last year

PremiumThe Fly

Amarin reports Q3 EPS (2c) vs (6c) last year

6M ago

Amarin issues statement related to recent action by FDA for fenofibrate drugs

PremiumThe Fly

Amarin issues statement related to recent action by FDA for fenofibrate drugs

6M ago

Is AMRN a Buy, Before Earnings?

PremiumPre-EarningsIs AMRN a Buy, Before Earnings?

6M ago

Amarin Appoints David Keenan as COO

Company Announcements

Amarin Appoints David Keenan as COO

6M ago

Amarin, HLS Therapeutics present REDUCE-IT, EPA mechanistic data

The Fly

Amarin, HLS Therapeutics present REDUCE-IT, EPA mechanistic data

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >